Thermo Fisher Scientific reported better-than-expected Q2 earnings, with revenues up 3% year-over-year to $10.86 billion, driven by growth in life sciences and biopharma services. The company raised its 2025 full-year revenue guidance to between $43.6 billion and $44.2 billion, reflecting improved cost management and easing US-China tariff tensions. Adjusted EPS guidance was also increased, underpinning investor confidence and an 11% surge in the stock. CFO Stephen Williamson announced plans to retire in 2026, with Jim Meyer appointed as his successor.